Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Off-the-shelf cancer cell therapy clears major regulatory hurdle toward replacing custom-made treatments

Off-the-shelf cancer cell therapy clears major regulatory hurdle toward replacing custom-made treatments

New Capabilities

FDA fast-tracks Caribou Biosciences' immune-cloaked CAR-T therapy after 92% response rate in multiple myeloma patients

March 31st, 2026: FDA grants RMAT designation to CB-011

Overview

Every approved cancer cell therapy today requires extracting a patient's own cells, engineering them in a lab, and infusing them back. It costs over $400,000 and sometimes takes weeks — long enough that patients' cancer can grow while they wait.

On March 31, 2026, the FDA granted accelerated approval to CB-011, a donor-derived cell therapy designed to evade immune attack. In a Phase 1 trial, it achieved a 92% response rate in multiple myeloma patients, a blood cancer that kills roughly 12,000 Americans each year.

For a decade, researchers have worked on "off-the-shelf" cell therapies — mass-produced from donor cells and given to any patient on demand. CB-011's FDA approval advances this goal; if the approach works in larger trials, it could eliminate the cost and manufacturing barriers that now limit these treatments to a fraction of patients who need them.

Why it matters

If off-the-shelf cell therapies work as well as custom-made ones, cancer treatments that now take months and cost half a million dollars could become available in days.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

92%
Overall response rate
Proportion of previously untreated-by-similar-therapy myeloma patients who responded to CB-011 in Phase 1
75%
Complete response rate
Patients achieving complete or better response, comparable to best-in-class autologous therapies
91%
MRD negativity rate
Patients with no detectable cancer at one-in-100,000 cell sensitivity — a marker of deep remission
$465,000
Current autologous CAR-T cost
List price for Carvykti, a custom-made CAR-T therapy for myeloma that CB-011 aims to replace
0
Approved off-the-shelf CAR-T therapies
No allogeneic CAR-T has reached FDA approval — CB-011 is now closest to becoming the first

Voices

Curated perspectives — historical figures and your fellow readers.

Rachel Carson

Rachel Carson

(1907-1964) · Modernist · science

Fictional AI pastiche — not real quote.

"How remarkable that we have learned to instruct cells borrowed from one human body to shelter within another — nature's boundaries quietly redrawn by patient science. Yet I cannot help but wonder: as we engineer our cells to evade the immune system's ancient watchfulness, we would do well to remember that in biology, as in chemistry, the very mechanism that heals can also, under different circumstances, conceal."

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Rachel Haurwitz
Rachel Haurwitz
Leading CB-011 through accelerated FDA pathway
 Jennifer Doudna
Jennifer Doudna
Scientific advisor; Nobel Prize in Chemistry 2020 for CRISPR-Cas9
 Adriana Rossi
Adriana Rossi
Presented CB-011 dose escalation data at Tandem 2026

Organizations Involved

Caribou Biosciences
Caribou Biosciences
Biotechnology Company
Developer of CB-011; advancing through accelerated FDA pathway

A clinical-stage biotechnology company using proprietary CRISPR hybrid RNA-DNA (chRDNA) genome editing to develop off-the-shelf cell therapies for cancer and autoimmune diseases.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal Agency
Granted RMAT designation to CB-011

The federal agency responsible for evaluating and approving new medical therapies in the United States, including cell and gene therapies.
Allogene Therapeutics
Allogene Therapeutics
Biotechnology Company
Competitor developing allogeneic CAR-T; ALLO-715 myeloma program on FDA clinical hold

A pioneer in allogeneic CAR-T development whose BCMA-targeting myeloma therapy ALLO-715 showed a 71% response rate but faced regulatory setbacks, highlighting the challenge CB-011's immune-cloaking approach aims to solve.

Timeline

August 2017 March 2026

10 events Latest: March 31st, 2026 · 3 months ago
Tap a bar to jump to that date

  1. FDA grants RMAT designation to CB-011

    Latest Regulatory

    The FDA granted Regenerative Medicine Advanced Therapy designation to CB-011, providing the full suite of accelerated review pathways — including eligibility for accelerated approval — based on the Phase 1 clinical data. CB-011 now holds Fast Track, Orphan Drug, and RMAT designations.

  2. Translational data presented at Tandem 2026

    Scientific

    Clinical investigator Adriana Rossi presented CB-011 dose escalation results at the 2026 Tandem Meetings, including new translational data correlating CAR-T cell expansion with durable responses.

  3. Phase 1 data shows 92% response rate

    Clinical

    Caribou reported that 11 of 12 evaluable patients who had not previously received BCMA-targeting therapy responded to CB-011, with 75% achieving complete responses and 91% testing negative for minimal residual disease.

  4. Caribou narrows pipeline to focus on CB-010 and CB-011

    Corporate

    Caribou Biosciences announced a strategic pipeline prioritization, concentrating resources on its two lead programs — CB-010 for lymphoma and CB-011 for myeloma.

  5. FDA grants Fast Track designation to CB-011

    Regulatory

    The FDA granted Fast Track designation to CB-011 for relapsed or refractory multiple myeloma, providing the first expedited pathway for the therapy.

  6. First patient dosed in CaMMouflage trial

    Clinical

    Caribou dosed the first patient in the CaMMouflage Phase 1 trial, beginning dose escalation of CB-011 at 50 million CAR-T cells.

  7. FDA clears CB-011 to enter clinical trials

    Regulatory

    Caribou Biosciences received FDA clearance of its Investigational New Drug application for CB-011, enabling the CaMMouflage Phase 1 trial for relapsed or refractory multiple myeloma.

  8. Carvykti approved as second myeloma CAR-T

    Regulatory

    The FDA approved Carvykti (ciltacabtagene autoleucel) for heavily pretreated myeloma, with a 98% overall response rate — but at $465,000 per patient and a median 79-day wait from cell collection to infusion.

  9. First CAR-T therapy approved for multiple myeloma

    Regulatory

    The FDA approved Abecma (idecabtagene vicleucel), the first CAR-T therapy targeting BCMA for relapsed or refractory multiple myeloma, with a 73% overall response rate.

  10. FDA approves first-ever CAR-T therapy

    Regulatory

    The FDA approved Kymriah (tisagenlecleucel), a custom-made CAR-T therapy for childhood leukemia developed by Novartis and the University of Pennsylvania — the first cell-based gene therapy ever approved in the United States.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

August 2017

First CAR-T approval — Kymriah (2017)

The FDA approved Kymriah (tisagenlecleucel) for pediatric acute lymphoblastic leukemia, making it the first cell-based gene therapy ever approved in the United States. Developed by Carl June's team at the University of Pennsylvania and commercialized by Novartis, it proved that genetically reprogramming a patient's T cells could eliminate cancers that had resisted all other treatments. It was priced at $475,000 per patient.

Then

Five more autologous CAR-T therapies followed within five years, expanding into lymphoma and myeloma. The price point established a $400,000-plus benchmark for the category.

Now

CAR-T became standard of care for several blood cancers but remained limited by custom manufacturing — each product is made one patient at a time, creating bottlenecks, wait times, and costs that prevent most eligible patients from receiving treatment.

Why this matters now

CB-011 represents the next structural shift in this field: moving from one-at-a-time custom manufacturing to batch-produced, universally compatible therapy. If it succeeds, it addresses the access problem that has defined CAR-T since Kymriah's approval nine years ago.

December 2023

Casgevy — first CRISPR therapy approved (2023)

The FDA and U.K. regulators approved Casgevy (exa-cel), developed by CRISPR Therapeutics and Vertex Pharmaceuticals, as the first therapy using CRISPR-Cas9 gene editing to reach patients. It treated sickle cell disease by editing patients' own blood stem cells to reactivate fetal hemoglobin production.

Then

The approval validated CRISPR gene editing as a clinical tool and established regulatory precedent for therapies that permanently alter human DNA.

Now

It opened the door for more complex CRISPR-edited cell therapies — like CB-011, which uses four separate genome edits to build its immune-cloaked CAR-T cells.

Why this matters now

CB-011 builds directly on this regulatory precedent but pushes further: where Casgevy edits a patient's own cells with a single modification, CB-011 makes four edits to donor cells — inserting a cancer-targeting receptor, disabling the T-cell receptor, knocking out a rejection marker, and inserting an immune-cloaking protein. Each additional edit raises the bar for demonstrating safety, but the Casgevy approval showed regulators will accept gene-edited cell therapies.

2020–2022

Allogene's ALLO-715 clinical hold (2022)

Allogene Therapeutics, the most prominent early developer of off-the-shelf CAR-T therapies, tested ALLO-715 — a BCMA-targeting allogeneic CAR-T for myeloma — in its UNIVERSAL Phase 1 trial. The therapy showed a 71% response rate with 25% complete responses, but the FDA placed the program on clinical hold, casting doubt on whether allogeneic CAR-T could reach patients.

Then

The clinical hold stalled the leading allogeneic myeloma program and dampened investor confidence across the sector.

Now

It highlighted that aggressive lymphodepletion — Allogene's strategy to suppress host rejection — was not sufficient to make donor-derived cells persist long enough for durable responses.

Why this matters now

CB-011's immune-cloaking approach directly addresses the persistence problem that hobbled ALLO-715. Instead of temporarily suppressing the host immune system with drugs, CB-011 genetically engineers the donor cells themselves to evade detection. The contrast in response rates — CB-011's 92% versus ALLO-715's 71% — suggests the cloaking approach may be working.

Sources

(10)
+4
Investing News Network Caribou Biosciences Investor Relations OncLive National Cancer Institute SEER (National Cancer Institute) Kelonia Therapeutics Caribou Biosciences Investor Relations Caribou Biosciences Investor Relations Caribou Biosciences Investor Relations Caribou Biosciences Investor Relations